May 7, 2012
/PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Alexza Pharmaceuticals Inc. ("Alexza Pharmaceuticals" or the "Company") (NasdaqGM: ALXA -News), concerning whether the company and certain of its officers and directors have violated federal securities laws.
May 4, 2012
, shares Alexza Pharmaceuticals fell 20% or
to close at
after the FDA denied approval citing manufacturing deficiencies that affected its decision on Adasuve which is a drug designed to rapidly treat agitation related to schizophrenia and bipolar disorder. Alexza Pharmaceuticals said the FDA won't approve the drug after citing manufacturing problems at a company plant in
Mountain View, California
If you are aware of any facts relating to this investigation, or purchased shares of Alexza Pharmaceuticals, you can assist this investigation by contacting either
of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email
. Those who inquire by e-mail are encouraged to include their mailing address and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.
Contact:Bronstein, Gewirtz & Grossman, LLC
SOURCE Bronstein, Gewirtz & Grossman, LLC